Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Sees Large Increase in Short Interest

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) was the recipient of a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 54,264 shares, a growth of 112.1% from the December 15th total of 25,588 shares. Based on an average daily volume of 468,130 shares, the short-interest ratio is presently 0.1 days. Approximately 0.5% of the company’s shares are short sold. Approximately 0.5% of the company’s shares are short sold. Based on an average daily volume of 468,130 shares, the short-interest ratio is presently 0.1 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Radiopharm Theranostics stock. PNC Financial Services Group Inc. increased its holdings in shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) by 100.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,000 shares of the company’s stock after buying an additional 8,000 shares during the period. PNC Financial Services Group Inc. owned about 0.20% of Radiopharm Theranostics worth $88,000 at the end of the most recent quarter.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on RADX shares. B. Riley reaffirmed a “buy” rating and set a $16.00 target price (up previously from $13.00) on shares of Radiopharm Theranostics in a research note on Tuesday, December 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Radiopharm Theranostics in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $15.33.

Radiopharm Theranostics Stock Performance

NASDAQ RADX traded up $0.03 on Wednesday, reaching $5.20. The company’s stock had a trading volume of 43,454 shares, compared to its average volume of 148,299. The business has a 50-day moving average price of $4.97 and a 200 day moving average price of $5.29. Radiopharm Theranostics has a 52 week low of $3.50 and a 52 week high of $16.25.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.